Diseases

Evotec AG announced that the strategic transaction signed on 15 June 2018, to integrate Sanofi’s infectious disease unit including licensing-in the majority of Sanofi’s infectious…
Read More...

AMRI, a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life, has secured a…
Read More...

Translate Bio announced a multi-year research and development collaboration and exclusive licensing agreement with Sanofi Pasteur, the vaccines global business unit of Sanofi, to…
Read More...

Roche announced that the European Commission (EC) has approved Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy (the Perjeta-based regimen) for…
Read More...

MIT researchers have built an ingestible sensor equipped with genetically engineered bacteria that can diagnose bleeding in the stomach or other gastrointestinal problems. This…
Read More...

A first-in-human trial evaluating an experimental treatment for Ebola virus disease has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland. The Phase 1…
Read More...

Epigen Biosciences announced that it has entered into a collaboration agreement with Novo Nordisk A/S under which Novo Nordisk has licensed the LPA1 receptor antagonist EPGN696 for…
Read More...

The U.S. Food and Drug Administration (FDA) has accepted Sanofi's regulatory filing for Zynquista (sotagliflozin). The investigational oral treatment would be used in addition to…
Read More...

The US Food and Drug Administration (FDA) has approved Lokelma (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of adults with hyperkalaemia, a serious condition…
Read More...

The U.S. Food and Drug Administration approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney…
Read More...

Scientists have identified a mutation that gives cancer cells resistance to the breakthrough cancer treatment olaparib and other PARP inhibitors. The study findings could help…
Read More...

Ferring Pharmaceuticals announced the signing of an agreement giving the company the option to secure global commercialisation rights to nadofaragene firadenovec/Syn3 (rAd-IFN/Syn3), a…
Read More...

AstraZeneca and MedImmune announced high-level results from the Phase III ARCTIC trial in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who have…
Read More...

Sempre Health announced it's collaborating on a pilot program with Novo Nordisk to add diabetes medications to the Sempre Health affordability & engagement solution. Unlike…
Read More...

Novartis announces a five-year commitment to the fight against malaria in conjunction with the 7th Multilateral Initiative on Malaria Conference and the Malaria Summit of the…
Read More...

Sobi has received approval from Health Canada for a reduced dosing frequency for Orfadin (nitisinone). Orfadin is approved in combination with dietary restriction of tyrosine and…
Read More...

GSK and Orchard Therapeutics announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard,…
Read More...

Protagen AG and Gustave Roussy have announced the start of a collaboration to utilize Protagen’s SeroTag technology to help identify biomarkers that predict and monitor immune-related…
Read More...

MRI analysis of patients who received intradiscal injections of human dermal fibroblasts (HDFs) shows significant improvement in disc height after six months. This is the latest…
Read More...

Aditlys is the first medical technology firm to develop a bioresorbable vascular access solution for patients undergoing dialysis treatment for chronic kidney disease. Aditlys’…
Read More...